No photo of Anne E Laumann

View Scopus Profile

Anne E Laumann

  • 1119 Citations
1975 …2021

Research output per year

If you made any changes in Pure these will be visible here soon.

Personal profile

Research Interests

Dr. Laumann's clinical interests include the diagnosis and treatment of complex medical dermatologic disorders including collagen vascular, psychocutaneous, and genital diseases. She has a particular interest in fibrosing, pruritic and other disorders related to renal dysfunction, as well as Raynaud's syndrome. She has an ongoing interest in the various aspects of the application of body art and how this may be used to help functioning. Currently, she is involved with other research studies related to psoriasis, atopic dermatitis, nephrogenic systemic fibrosis, systemic sclerosis, morphea, dermatomyositis, and lupus erythematosus.

Certifications and Licenses

Dermatology

Training Experience

1979Residency, University of Chicago Hospitals

Education/Academic qualification

MRCP (UK), Royal College of Physicians of the UK

… → 1973

MBChB, University of Birmingham

… → 1968

Research interests

  • Dermatology

Fingerprint Dive into the research topics where Anne E Laumann is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 4 Similar Profiles

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Grants

Prot #GS-US-436-4092: A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of Filgotinib and GS-9876 in Female Subjects with Moderately-to-Severely Active Cutaneous Lupus Erythematosus (CLE)

Laumann, A. E.

ICON Clinical Research, L.P., Gilead Sciences, Inc.

7/27/17 → 7/27/20

Project: Research project

Prot #R668-AD-1225: An Open-Label Study of Dupilumab in Patients with Atopic Dermatitis Who Participated in Previous Dupilumab Clinical Trials

Laumann, A. E.

Parexel, Regeneron Pharmaceuticals, Inc.

5/5/14 → 5/5/20

Project: Research project

Prot# P10-023: A 10-Year, Post-Marketing, Observational, Registry of HUMIRA (Adalimumab) in Adult Patients With Chronic Plaque Psoriasis (Ps)

Laumann, A. E. & West, D. P.

United BioSource LLC, Abbott Laboratories

4/20/09 → 12/31/21

Project: Research project

Prot #C0168Z03: A Multicenter, Open Registry of Patients with Psoriasis Who are Candidates for Systemic Therapy Includes Biologics

Paller, A., Singri, P., West, D. P., Amin, A. Z. & Laumann, A. E.

Mapi USA, Inc., Janssen Biotech, Inc.

3/2/09 → 3/2/21

Project: Research project

Prot #8400-211: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial of IMO-8400 In Patients with Dermatomyositis

Laumann, A. E.

Parexel, Idera Pharmaceuticals, Inc.

3/14/16 → 3/14/19

Project: Research project

Research Output

Association of dermatomyositis with systemic and opportunistic infections in the United States

Ren, Z., Laumann, A. E. & Silverberg, J. I., Jul 5 2019, In : Archives of Dermatological Research. 311, 5, p. 377-387 11 p.

Research output: Contribution to journal › Article

    • 2 Scopus citations

    Melanoma subsequent to natalizumab exposure: A report from the RADAR (Research on Adverse Drug events And Reports) program

    Kelm, R. C., Hagstrom, E. L., Mathieu, R. J., Orrell, K. A., Serrano, L., Mueller, K. A., Laumann, A. E., West, D. P. & Nardone, B., Mar 2019, In : Journal of the American Academy of Dermatology. 80, 3, p. 820-821 2 p.

    Research output: Contribution to journal › Article

    2 Scopus citations

    Cardiovascular and cerebrovascular comorbidities of juvenile dermatomyositis in US children: An analysis of the National Inpatient Sample

    Silverberg, J. I., Kwa, L., Kwa, M. C., Laumann, A. E. & Ardalan, K., Apr 1 2018, In : Rheumatology (United Kingdom). 57, 4, p. 694-702 9 p.

    Research output: Contribution to journal › Article

    • 8 Scopus citations

    History and Epidemiology of Tattoos and Piercings: Legislation in the United States and in Europe

    Laumann, AE., Kluger, N. & Perez-Cotapos, ML., 2018, Dermatologic Complications with Body Art Second edition 2018. De Cuyper, C. (ed.). Heidelberg: Springer, p. 1-19

    Research output: Chapter in Book/Report/Conference proceeding › Chapter

    Inflammatory bowel disease events after exposure to interleukin 17 inhibitors secukinumab and ixekizumab: Postmarketing analysis from the RADAR (“Research on Adverse Drug events And Reports”) program

    Orrell, K. A., Murphrey, M., Kelm, R. C., Lee, H. H., Pease, D. R., Laumann, A. E., West, D. P. & Nardone, B., Oct 2018, In : Journal of the American Academy of Dermatology. 79, 4, p. 777-778 2 p.

    Research output: Contribution to journal › Article

    9 Scopus citations